Sign in
4

Changes in Ownership

ArriVent BioPharma, Inc. Filed Acc 0001104659-26-010473

Options or other derivatives

  • Chief Financial Officer acquired 140,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Kung Winston · Chief Financial Officer

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-02-02 Grant or award : show line 1 in the form Stock Option (right to buy) +140,000 140,000 D
Loading xslF345X05/tm265104-2_4seq1.xml…